Salmeterol

Source: www.moreover.com --- 19 days ago
my personal edition> copd > news E-Mail this DGNews to a colleague DGNews NEW YORK -- August 15, 2008 -- For the first time, a drug therapy appears to reduce lung function loss in patients with moderate to severe chronic obstructive pulmonary ...

Source: www.ncbi.nlm.nih.gov --- 15 days ago
Related Articles Asthma exacerbations in African Americans treated for 1 year with combination fluticasone propionate and Salmeterol or fluticasone propionate alone. Curr Med Res Opin. 2008 Jun;24(6):1669-82 Authors: Bailey W, Castro M, Matz J, White M, Dransfield M, Yancey S, Ortega H OBJECTIVE: This long-term prospective study was conducted in African Americans with persistent asthma to examine the safety and effectiveness of the combination of the inhaled corticosteroid, fluticasone propionate (FP), and the long-acting beta-agonist, Salmeterol, compared with FP alone. RESEARCH AND DESIGN METHODS: This was a randomized, double-blind, parallel group, multi-center trial in adolescent and adult subjects >/=12 years of age symptomatic on a low dose of an inhaled corticosteroid (ICS). The study consisted of a 2-week screening period on low dose ICS; a 4-week open-label FP 250 mcg twice daily (BID) run-in; a 52-week double-blind period (FP/Salmeterol [FSC] 100/50 mcg [n=239] or FP 100 mcg [n=236] BID), and a 4-week FP 250 mcg BID run-out period. Annualized exacerbation rate was the primary outcome for comparing the two treatments. Other measures of asthma control included peak expiratory flow, asthma symptoms, and albuterol use. Safety was assessed through adverse events. RESULTS: Exacerbation rates were not significantly different in those treated with FSC 100/50 mcg (0.449 per year) compared with FP 100 mcg (0.529 per year, p=0.169). Whe ...

Source: caartman.reproducting.com --- 34 days ago
No apparent Salmeterol xinafoate fluticasone propionate in the. Whitney houston picture propionate combination in the Gaining Optimal Asthma controL study. More frequent haemodialysis can improve both survival and quality of life of patients with chronic kidney disease. Case Reports from Journal of Drugs in Dermatology in Array provided free by LookSmart Find Articles. [...] ...

Source: au.rd.yahoo.com --- 49 days ago
NEW YORK (Reuters Health) - Patients with chronic asthma who use the Salmeterol on a daily basis are at increased risk for serious adverse events, researchers conclude in the latest issue of The Cochrane Library. ...

Source: www.ncbi.nlm.nih.gov --- 43 days ago
Related Articles Combination fluticasone and Salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children. Cochrane Database Syst Rev. 2008;(3):CD004106 Authors: Lasserson TJ, Cates CJ, Ferrara G, Casali L BACKGROUND: Combination therapies are frequently recommended as maintenance therapy for people with asthma, whose disease is not adequately controlled with inhaled steroids. Fluticasone/Salmeterol (FP/SAL) and budesonide/formoterol (BUD/F) have been assessed against their respective monocomponents, but there is a need to compare these two therapies on a head-to-head basis. OBJECTIVES: To estimate the relative effects of fluticasone/Salmeterol and budesonide/formoterol in terms of asthma control, safety and lung function. SEARCH STRATEGY: We searched the Cochrane Airways Group register of trials with prespecified terms. We performed additional hand searching of manufacturers' web sites and online trial registries. Searches are current to May 2008. SELECTION CRITERIA: Randomised studies comparing fixed dose FP/SAL and BUD/F were eligible, for a minimum of 12 weeks. Crossover studies were excluded. Our primary outcomes were: i) exacerbations requiring oral steroid bursts, ii) hospital admission and iii) serious adverse events. DATA COLLECTION AND ANALYSIS: Two authors independently assessed studies for inclusion in the review. We combined continuous data outcomes with a mean difference (M ...

Source: www.ncbi.nlm.nih.gov --- 60 days ago
Related Articles Salmeterol with fluticasone enhances the suppression of IL-8 release and increases the translocation of glucocorticoid receptor by human neutrophils stimulated with cigarette smoke. J Mol Med. 2008 Jul 4; Authors: Mortaz E, Rad MV, Johnson M, Raats D, Nijkamp FP, Folkerts G The combination of inhaled corticosteroids and long-acting beta(2)-adrenoceptor agonists is increasingly used in chronic obstructive pulmonary disease (COPD). Recently, we have demonstrated that combination of Salmeterol and fluticasone propionate (FP) additionally suppress the production of IL-8 by human monocyte. In this study, the molecular mechanism behind the effectiveness of this combination therapy is investigated in human neutrophils. Human neutrophils were preincubated with Salmeterol or FP or the combination. The amount of interleukin-8 (IL-8), elastase and matrix metalloproteinases (MMP)-2 and -9 releases, and reactive oxygen species (ROS) generation and expression of MAP kinase phosphatase (MKP-1) and glucocorticoid receptor (GR) were determined. Cigarette smoke medium (CSM) induces an increased expression of CXC receptors and the production of ROS that may explain the strong production of IL-8 by neutrophils. The expression of CXC receptors, the production of ROS, and the release of elastase and MMP-2 and -9 were not influenced by Salmeterol, FP, or the combination. Interestingly, the combination therapy had an additive suppressive effe ...

Source: www.ncbi.nlm.nih.gov --- 43 days ago
Related Articles Regular treatment with Salmeterol for chronic asthma: serious adverse events. Cochrane Database Syst Rev. 2008;(3):CD006363 Authors: Cates CJ, Cates MJ BACKGROUND: Epidemiological evidence has suggested a link between beta-agonists and increases in asthma mortality. There has been much debate about possible causal links for this association, and whether regular (daily) long-acting beta(2)-agonists are safe. OBJECTIVES: The aim of this review is to assess the risk of fatal and non-fatal serious adverse events in trials that randomised patients with chronic asthma to regular Salmeterol versus placebo or regular short-acting beta(2)-agonists. SEARCH STRATEGY: Trials were identified using the Cochrane Airways Group Specialised Register of trials. Web sites of clinical trial registers were checked for unpublished trial data and FDA submissions in relation to Salmeterol were also checked. The date of the most recent search was October 2007. SELECTION CRITERIA: Controlled parallel design clinical trials on patients of any age and severity of asthma were included if they randomised patients to treatment with regular Salmeterol and were of at least 12 weeks duration. Concomitant use of inhaled corticosteroids was allowed, as long as this was not part of the randomised treatment regimen. DATA COLLECTION AND ANALYSIS: Two authors independently selected trials for inclusion in the review. Outcome data was extracted by one author ...

Source: www.ncbi.nlm.nih.gov --- 12 days ago
Related Articles [Budesonide/formoterol maintenance and reliever therapy. A new treatment approach for adult patients with asthma] Med Klin (Munich). 2008 May 15;103(5):299-310 Authors: Korn S, Vogelmeier C, Buhl R BACKGROUND: An inhaled corticosteroid (ICS) or an ICS/long-acting beta(2)-agonist (LABA) combination plus short-acting beta(2)-agonist (SABA) as needed for symptom relief is recommended for persistent asthma. Additionally, budesonide/formoterol maintenance and reliever therapy (Symbicort) SMART, AstraZeneca, Sweden) has been approved for adults in the European Union. This option is well tolerated and offers greater reductions in asthma exacerbations together with similar improvements in daily symptom control, at a lower overall steroid load, compared with fixed-dose ICS/LABA plus SABA. METHODS: Two large clinical trials investigated the use of budesonide/formoterol as maintenance and reliever compared with medium or high doses of an ICS/LABA combination as controller plus SABA as reliever in adults (aged >or= 18 years). COMPASS was a 6-month, double-blind, randomized trial, while COSMOS was a 1-year, dose titration study which reflected routine clinical practice. RESULTS: Among adults, the studies confirmed a 21-39% reduction in severe exacerbations in patients treated with budesonide/formoterol maintenance and reliever therapy compared with titrated Salmeterol/fluticasone plus SABA (COSMOS) or fixed higher budesonide/formo ...

Source: www.medscape.com --- 47 days ago
A Cochrane systematic review shows that Salmeterol increases the risk for serious adverse events in patients with asthma. Medscape Medical News ...

Source: www.medicalnewstoday.com --- 49 days ago
People with asthma who regularly use Salmeterol are at a greater risk of non-fatal serious adverse events than those using placebos. This conclusion was arrived at by a team of Cochrane Researchers who drew together data from 26 trials involving 62,630 patients. ...

Source: www.medicalnewstoday.com --- 19 days ago
Study results published show that treatment with Seretide®/Advair® (Salmeterol/fluticasone propionate 50/500mcg) can slow the progression of Chronic Obstructive Pulmonary Disease (COPD) by significantly lowering a patient's rate of lung function decline compared with those receiving placebo. ...

Source: www.newsisfree.com --- 51 days ago
[in Doctor's Guide: General ] ...

Source: suctrevietnam.com --- 34 days ago
Các bệnh nhân mắc bệnh hen suyễn kinh niên dùng Salmeterol (một loại thuốc có tác dụng làm giãn phế quản) để điều trị có thể gặp phải những tác dụng xấu do thuốc đem lại. ...

Source: www.healthcentral.com --- 47 days ago
Patients with chronic asthma who use the Salmeterol on a daily basis are at increased risk for serious adverse events, researchers conclude in the latest issue of The Cochrane Library. ...

Source: www.medpagetoday.com --- 50 days ago
LONDON -- For chronic asthma, twice-daily use of Salmeterol (Serevent) was associated with small but significant increases in serious adverse events, a meta-analysis showed. ...

Source: sanantonio.injuryboard.com --- 8 days ago
I found an interesting article from MSN Health & Fitness regarding Eight Drugs Doctors Would Never Take . Most interesting to me was that two of the drugs listed were drugs I've taken in the past and never had any idea I shouldn't have taken them. More importantly -- they are still on the market and you may also be taking them. The eight drugs and why you shouldn't be taking them are: 1. Advair - asthma medicine. Advair contains LABA, the long acting beta-agonist Salmeterol. Apparently, regular use of LABAs can increase the severity of your next asthma attack. 2. Avandia - diabetes medicine. Also known as rosiglitazone - taken for at least a year can increase your chance of heart failure or a heart attack by 109% and 42% respectively. 3. Celebrex - nicknamed "super aspirin". Also, known for it's side effects of increased risk of stomach bleeding, kidney trouble and liver damage. Celebrex is still available, although two other COX-2 inhibitors, Bextra and Vioxx were pulled off the market. 4. Ketek - used for respiratory infections can cause heart rhythm problems and can lead to liver disease. 5 and 6. Prilosec and Nexium - proton-pump inhibitors - are very effective at stopping acid production in your stomach. A lack of acid can increase your risk of pneumonia. The burning sensation you feel in your chest is the same stuff that kills bacteria and viruses. Also likely, is elevated risk of bone loss increasing your risk of fractures. ...

Source: www.bio-medicine.org --- 19 days ago
For the first time, a drug therapy appears to reduce lung function loss in patients with moderate to severe chronic obstructive pulmonary disease (COPD), according to the results of a randomized, double-blind, placebo-controlled trial in 42 countries. The Toward a Revolution in COPD Health (TORCH) study investigated the effects of combined Salmeterol, a -agonist, and fluticasone propiniate... ...

Source: allnurses.com --- 21 days ago
The July 2008 posting includes 35 drug products with safety labeling changes to the following sections: BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, and PATIENT PACKAGE INSERTS, and MEDICATION GUIDES. The "Summary Page" provides a listing of drug names and safety labeling sections revised: http://www.fda.gov/medwatch/safety/2008/jul08_quickview.htm The "Detailed View Page" identifies safety labeling sections and subsections revised along with a brief summary of new or modified safety information to the BOXED WARNING, CONTRAINDICATIONS, and/or WARNINGS sections: http://www.fda.gov/medwatch/safety/2008/jul08.htm In July 2008, the following drugs had modifications to the BOXED WARNING section: * Baraclude (entecavir) Tablets and Oral Solution * Exforge (amlodipine and valsartan) Tablets * Strattera (atomoxetine hydrochloride) Capsules * Tykerb (lapatinib) Tablets * Ziagen (abacavir sulfate) Tablets and Oral Solution * In addition, the following products in July 2008 had changes to MEDICATION GUIDES: * Advair HFA (fluticasone propionate and Salmeterol) Inhalation Aerosol for Oral Inhalation Only * Enbrel (etanercept) for Subcutaneous Injection * EC-Naprosyn (naproxen delayed-release tablets), Naprosyn (naproxen tablets), Anaprox/Anaprox DS (naproxen sodium tablets), and Naprosyn (naproxen suspension) * Strattera (atomoxetine hydrochloride) Capsules * Symbicort (budesonide and formoterol fumarate dihydrate) I ...

Source: newsbigget.clickblog.com.br --- 5 days ago
Bush Says Russia Must Honor Georgia California preschool for all Agreement Update. Video Olympic Minute Phelps Ties Spitz, and More. Does not cure HIV or help prevent passing HIV to others. Pepcid ACR famotidine, TagametR cimetidine, or ZantacR ranitidine, AdvairR Ordenadores portatiles airis propionate and Salmeterol. Stones include pain in the side, blood in the [...] ...

Source: www.dukehealth.org?from=RSS --- 26 days ago
The purpose of this study is to examine systemic changes in metabolism, hormones, and inflammation following standard treatment with combination of Salmeterol 50 mcg and fluticasone propionate 250 mcg. ...